GlassScriptPhysician profile
Stefanie J Lamanna
NPI 1548205644
$4,486.17
in general payments reported to CMS, 2019-2025
28 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $860 · 2022: $826 · 2023: $1,323 · 2024: $1,159 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $597.26 | 2021-2025 | Wegovy |
| Gilead Sciences, INC. | $470.19 | 2022-2025 | Biktarvy |
| Amgen INC. | $344.40 | 2021-2023 | Tezspire, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $238.03 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $220.53 | 2021-2023 | Uptravi, Opsumit |
| Abbvie INC. | $220.12 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.26 | 2021-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $185.05 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $158.82 | 2023-2024 | Tezspire |
| Adma Biomanufacturing LLC | $151.30 | 2024 | |
| Alk-Abello, INC | $136.32 | 2021 | |
| X4 Pharmaceuticals, INC. | $135.00 | 2024 | Xolremdi |
| Cvrx, INC. | $133.31 | 2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Neurocrine Biosciences, INC. | $124.99 | 2023 | Ongentys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $124.99 | 2024 | Joenja |
| Biocryst US Sales Co., LLC | $124.92 | 2022 | |
| Horizon Therapeutics Plc | $123.23 | 2021 | |
| Sanofi US Services INC. | $119.81 | 2025 | |
| Insmed, INC. | $114.64 | 2023 | Arikayce |
| Abbott Laboratories | $92.54 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $67.63 | 2022 | |
| Coloplast Corp | $67.37 | 2024 | |
| Eisai INC. | $61.12 | 2024 | |
| Medtronic, INC. | $56.60 | 2023 | Interstim |
| Mylan Specialty L.P. | $49.07 | 2024 | Yupelri |
| Exact Sciences Corporation | $40.33 | 2024 | Cologuard Collection Kit |
| Organon LLC | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Lamanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.